| Generic name | Glasdegib |
| Brand name(s), other common name(s) | DaurismoTM |
| Drug type | Hedgehog pathway inhibitor |
| How the drug is given | By mouth |
Indications and Usage
Glasdegib is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Limitation of Use: Glasdegib has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.
Side effects needing medical attention
Anemia, fatigue, hemorrhage, febrile neutropenia, musculoskeletal pain, nausea, edema, thrombocytopenia, difficult or labored breathing (dyspnea), decreased appetite, distortion of the sense of taste (dysgeusia), mucositis, constipation, and rash.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.